肿瘤免疫检查点成像:迈向个体化免疫治疗的游戏规则改变者?
免疫检查点阻断在多种癌症中显示抗肿瘤活性,但并非所有患者均等获益,且可能伴随明显副作用,因此需谨慎选择患者并监测治疗反应。本文综述了免疫检查点特异性分子成像作为患者选择和疗效评估工具的最新进展。
要点
- 免疫检查点阻断并非所有患者均等获益,且可能伴随明显副作用。
- 免疫检查点特异性分子成像正被越来越多地研究用于患者选择和疗效评估。
- 本文提供了免疫检查点成像当前进展的综述。
核心结论
- 免疫检查点阻断在多种癌症中显示抗肿瘤活性,但并非所有患者均等获益,且可能伴随明显副作用,因此需谨慎选择患者并监测治疗反应。
- 免疫检查点特异性分子成像正被越来越多地研究作为患者选择和疗效评估的工具。
研究设计与样本
- 本文为综述,提供免疫检查点成像当前进展的概述。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint blockade represents a promising approach in oncology, showing antitumor activities in various cancers. However, although being generally far better tolerated than classic cytotoxic chemotherapy, this treatment, too, may be accompanied by considerable side effects and not all patients benefit equally. Therefore, careful patient selection and monitoring of the treatment response is mandatory. At present, checkpoint-specific molecular imaging is being increasingly investigated as a tool for patient selection and response evaluation. Here, an overview of the current developments in immune checkpoint imaging is provided.
引用
- Lütje S, Feldmann G, Essler M, et al. Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy? J Nucl Med. 2020. PMID: 31924724. doi:10.2967/jnumed.119.237891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。